Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Azithramycine
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Kanazawa S et al. | Azithromycin and bronchiolitis obliterans. | 2004 | Am. J. Respir. Crit. Care Med. | pmid:14982826 |
Tsai WC et al. | Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. | 2004 | Am. J. Respir. Crit. Care Med. | pmid:15361366 |
Jeong BH et al. | Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. | 2015 | Am. J. Respir. Crit. Care Med. | pmid:25393520 |
Restrepo MI and Anzueto A | Reply: Azithromycin: We're there! | 2014 | Am. J. Respir. Crit. Care Med. | pmid:25360733 |
Albert RK et al. | Azithromycin: We're there! | 2014 | Am. J. Respir. Crit. Care Med. | pmid:25360732 |
Verleden GM et al. | Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. | 2006 | Am. J. Respir. Crit. Care Med. | pmid:16741151 |
Barker PM et al. | Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium. | 2005 | Am. J. Respir. Crit. Care Med. | pmid:15657462 |
Choi GE et al. | Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. | 2012 | Am. J. Respir. Crit. Care Med. | pmid:22878281 |
Restrepo MI and Anzueto A | Macrolide antibiotics for prevention of chronic obstructive pulmonary disease exacerbations: are we there yet? | 2014 | Am. J. Respir. Crit. Care Med. | pmid:24983214 |
Binder AM et al. | Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. | 2013 | Am. J. Respir. Crit. Care Med. | pmid:23927602 |
Lococo F et al. | Hemoptysis and Progressive Dyspnea in a 67-Year-Old Woman with History of Renal Transplantation. | 2016 | Am. J. Respir. Crit. Care Med. | pmid:26681504 |
Albert RK and Schuller JL | Macrolide antibiotics and the risk of cardiac arrhythmias. | 2014 | Am. J. Respir. Crit. Care Med. | pmid:24707986 |
Angel LF et al. | Azithromycin in bronchiolitis obliterans: is the evidence strong enough? | 2006 | Am. J. Respir. Crit. Care Med. | pmid:16467178 |
Han MK et al. | Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. | 2014 | Am. J. Respir. Crit. Care Med. | pmid:24779680 |
Meyer M et al. | Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. | 2009 | Am. J. Respir. Cell Mol. Biol. | pmid:19244203 |
Halldorsson S et al. | Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection. | 2010 | Am. J. Respir. Cell Mol. Biol. | pmid:19372247 |
Bergamini G et al. | Effects of azithromycin on glutathione S-transferases in cystic fibrosis airway cells. | 2009 | Am. J. Respir. Cell Mol. Biol. | pmid:19097986 |
Kadova Z et al. | IL-1 receptor blockade alleviates endotoxin-mediated impairment of renal drug excretory functions in rats. | 2015 | Am. J. Physiol. Renal Physiol. | pmid:25503728 |
Fan LC et al. | Macrolides protect against infection via inhibition of inflammasomes. | 2017 | Am. J. Physiol. Lung Cell Mol. Physiol. | pmid:28684545 |
Shinkai M et al. | Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. | 2006 | Am. J. Physiol. Lung Cell Mol. Physiol. | pmid:16085674 |
Blau H et al. | Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line. | 2007 | Am. J. Physiol. Lung Cell Mol. Physiol. | pmid:17012372 |
Tarran R et al. | Nonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion. | 2013 | Am. J. Physiol. Lung Cell Mol. Physiol. | pmid:23542952 |
Uy HS et al. | Infectious crystalline keratopathy and endophthalmitis secondary to Mycobacterium abscessus in a monocular patient with Stevens-Johnson syndrome. | 1999 | Am. J. Ophthalmol. | pmid:10030567 |
Kuehne JJ et al. | Corneal pharmacokinetics of topically applied azithromycin and clarithromycin. | 2004 | Am. J. Ophthalmol. | pmid:15488779 |
Bosch-Driessen LH et al. | A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. | 2002 | Am. J. Ophthalmol. | pmid:12095805 |
Stewart WC et al. | Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. | 2010 | Am. J. Ophthalmol. | pmid:20813346 |
Wolle MA et al. | Impact of Trichiasis surgery on physical functioning in Ethiopian patients: STAR trial. | 2011 | Am. J. Ophthalmol. | pmid:21333268 |
Katusic D et al. | Azithromycin vs doxycycline in the treatment of inclusion conjunctivitis. | 2003 | Am. J. Ophthalmol. | pmid:12654359 |
Abelson MB et al. | Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. | 2008 | Am. J. Ophthalmol. | pmid:18374301 |
Ness PJ et al. | An anterior chamber toxicity study evaluating Besivance, AzaSite, and Ciprofloxacin. | 2010 | Am. J. Ophthalmol. | pmid:20678751 |
Sutton AL et al. | Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis. | 2015 | Am. J. Obstet. Gynecol. | pmid:25595580 |
Andrews WW et al. | Interconceptional antibiotics to prevent spontaneous preterm birth: a randomized clinical trial. | 2006 | Am. J. Obstet. Gynecol. | pmid:16522388 |
Jacobson GF et al. | A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. | 2001 | Am. J. Obstet. Gynecol. | pmid:11408852 |
Tita AT et al. | Impact of interconception antibiotics on the endometrial microbial flora. | 2007 | Am. J. Obstet. Gynecol. | pmid:17346530 |
Grigsby PL et al. | Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. | 2012 | Am. J. Obstet. Gynecol. | pmid:23111115 |
Ward E and Duff P | A comparison of 3 antibiotic regimens for prevention of postcesarean endometritis: an historical cohort study. | 2016 | Am. J. Obstet. Gynecol. | pmid:26901276 |
Gray RH et al. | Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. | 2001 | Am. J. Obstet. Gynecol. | pmid:11717659 |
Ramsey PS et al. | Maternal and transplacental pharmacokinetics of azithromycin. | 2003 | Am. J. Obstet. Gynecol. | pmid:12634646 |
Lin KJ et al. | Safety of macrolides during pregnancy. | 2013 | Am. J. Obstet. Gynecol. | pmid:23254249 |
Tita AT et al. | Impact of extended-spectrum antibiotic prophylaxis on incidence of postcesarean surgical wound infection. | 2008 | Am. J. Obstet. Gynecol. | pmid:18771992 |
Johnson RB | The role of azalide antibiotics in the treatment of Chlamydia. | 1991 | Am. J. Obstet. Gynecol. | pmid:1645503 |
Kelsey JJ et al. | Presence of azithromycin breast milk concentrations: a case report. | 1994 | Am. J. Obstet. Gynecol. | pmid:8178871 |
Keelan JA et al. | Maternal-amniotic-fetal distribution of macrolide antibiotics following intravenous, intramuscular, and intraamniotic administration in late pregnant sheep. | 2011 | Am. J. Obstet. Gynecol. | pmid:21481833 |
Tita AT et al. | Clinical trial of interconceptional antibiotics to prevent preterm birth: subgroup analyses and possible adverse antibiotic-microbial interaction. | 2007 | Am. J. Obstet. Gynecol. | pmid:17904962 |
Winton JC and Twilla JD | Sudden cardiac arrest in a patient on chronic methadone after the addition of azithromycin. | 2013 | Am. J. Med. Sci. | pmid:23103438 |
Devasia RA et al. | Compliance with azithromycin versus erythromycin in the setting of a pertussis outbreak. | 2009 | Am. J. Med. Sci. | pmid:19301451 |
Moellering RC | Introduction: revolutionary changes in the macrolide and azalide antibiotics. | 1991 | Am. J. Med. | pmid:1656735 |
Mallory SB | Azithromycin compared with cephalexin in the treatment of skin and skin structure infections. | 1991 | Am. J. Med. | pmid:1656741 |
Hopkins S | Clinical toleration and safety of azithromycin. | 1991 | Am. J. Med. | pmid:1656742 |
Schentag JJ and Ballow CH | Tissue-directed pharmacokinetics. | 1991 | Am. J. Med. | pmid:1656743 |